Hypercalcemia – Pipeline Review, H2 2012

  • July 2012
  • -
  • Global Markets Direct
  • -
  • 35 pages

Hypercalcemia – Pipeline Review, H2 2012



Summary



Global Markets Direct’s, 'Hypercalcemia - Pipeline Review, H2 2012', provides an overview of the Hypercalcemia therapeutic pipeline. This report provides information on the therapeutic development for Hypercalcemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercalcemia. 'Hypercalcemia - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope


- A snapshot of the global therapeutic scenario for Hypercalcemia.
- A review of the Hypercalcemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypercalcemia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Hypercalcemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypercalcemia pipeline depth and focus of Hypercalcemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hypercalcemia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Hypercalcemia 7
Hypercalcemia Therapeutics under Development by Companies 9
Hypercalcemia Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Hypercalcemia Therapeutics - Products under Development by Companies 13
Hypercalcemia Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Hypercalcemia Therapeutics Development 15
Genta Incorporated 15
Med Discovery SA 16
Hypercalcemia - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
G4544 - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Parathyroid Hormone (1-34) - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
MDAB16 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Hypercalcemia Therapeutics - Dormant Products 26
Hypercalcemia - Product Development Milestones 27
Featured News and Press Releases 27
Dec 02, 2009: Genta to Support Initiation of New Clinical Trial using Ganite as Treatment for Life-Threatening Infections in Patients with Cystic Fibrosis 27
Jun 04, 2007: Phase 2 Clinical Results of Ganiteandreg; Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO 27
Mar 07, 2007: Genta and IDIS Announce Global Ex-U.S. Agreement for Named Patient/Compassionate Use Distribution of Ganiteandreg; and Genasenseandreg; 28
Mar 02, 2006: Randomized Trial Shows Ganiteandreg; Effective When Compared with A Leading Bisphosphonate in Patients with Cancer-Related Hypercalcemia 29
Dec 23, 2004: NPS Completes $175 Million Note Offering Backed By Sensipar Royalties 29
Dec 05, 2004: Ganiteandreg; Activity in Patients with Advanced Non-Hodgkin's Lymphoma Presented at Hematology Meeting 30
Jul 30, 2004: Mimpara -- Cinacalcet HCl -- Receives Positive Regulatory Opinion For Approval In Europe 30
Apr 08, 2004: Sensipar Pivotal Studies In Over 700 Patients Published In New England Journal Of Medicine 31
Mar 25, 2004: GenasenseTM and GaniteTM Featured in Presentations at the Annual Meeting of the American Association for Cancer Research 32
Sep 18, 2003: FDA Approves Genta's First Product, Ganite, for the Treatment of Cancer - Related Hypercalcemia 32
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35

List of Tables

Number of Products Under Development for Hypercalcemia, H2 2012 7
Products under Development for Hypercalcemia - Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Genta Incorporated, H2 2012 15
Med Discovery SA, H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Hypercalcemia Therapeutics - Dormant Products 26

List of Figures

Number of Products under Development for Hypercalcemia, H2 2012 7
Products under Development for Hypercalcemia - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Purchase Reports From Reputable Market Research Publishers

Arno Therapeutics, Inc. - Product Pipeline Review - 2014

Arno Therapeutics, Inc. - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • July 2014
  • by Global Markets Direct

Arno Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Arno Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Arno Therapeutics, Inc.'s ...

VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014

VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • July 2014
  • by Global Markets Direct

VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘VistaGen Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the VistaGen Therapeutics ...

Esperion Therapeutics, Inc. - Product Pipeline Review - 2014

Esperion Therapeutics, Inc. - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • July 2014
  • by Global Markets Direct

Esperion Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Esperion Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Esperion Therapeutics, ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.